Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary NeuroMetrix Announces One-for-Ten Reverse Split
Shares of Common Stock and Certain Warrants Will Begin Trading on a Split-Adjusted Basis on November 19, 2019 WOBURN, Mass. , Nov. 18, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced the effectiveness of a one-for-ten reverse split of its common stock.
View HTML
Toggle Summary NeuroMetrix Reports Q3 2019 Financial Results
WOBURN, Mass. , Oct. 17, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO ) today reported financial and business highlights for the quarter ended September 30, 2019 . The Company develops and commercializes products for the chronic pain and diabetes markets that utilize neurostimulation
View HTML
Toggle Summary NeuroMetrix Announces Updates to Quell 2.0 Commercial Strategy
WOBURN, Mass. , Oct. 15, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), a health technology company that develops and commercializes products for the chronic pain and diabetes markets, today announced important updates to its Quell ® 2.0 commercial strategy.  This novel wearable device
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for Third Quarter 2019 Financial Results Conference Call
WOBURN, Mass. , Oct. 10, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2019 third quarter financial results before the opening of the market on Thursday, October 17, 2019 . The Company will host a conference call at 8:00 a.m., Eastern Time on
View HTML
Toggle Summary NeuroMetrix Reports Q2 2019 Financial Results
WALTHAM, Mass. , July 18, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO ) today reported financial and business highlights for the quarter ended June 30, 2019 . The Company develops and markets novel therapies for chronic health conditions employing neurostimulation and digital medicine.
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for Second Quarter 2019 Financial Results Conference Call
WALTHAM, Mass. , July 11, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2019 second quarter financial results before the opening of the market on Thursday, July 18, 2019 . The Company will host a conference call at 8:00 a.m., Eastern Time on
View HTML
Toggle Summary NeuroMetrix Provides Strategic Update
WALTHAM, Mass. , June 27, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), a health technology company addressing chronic health conditions including chronic pain, sleep disorders and diabetes, today reported on its strategy of optimizing its commercial products while reducing operating
View HTML
Toggle Summary NeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable Technology
WALTHAM, Mass. , May 21, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,293,159 titled “Measuring the ‘on-skin’ time of a Transcutaneous Electrical Nerve Stimulator (TENS) device in order to minimize
View HTML
Toggle Summary NeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable Technology
WALTHAM, Mass. , May 07, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,279,179 titled “Transcutaneous Electrical Nerve Stimulator with automatic detection of user sleep-wake state.” The patent covers
View HTML
Toggle Summary NeuroMetrix Reports Q1 2019 Financial Results
WALTHAM, Mass. , April 25, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO ), today reported financial and business highlights for the quarter ended March 31, 2019 . The Company develops and markets novel therapies for chronic health conditions employing neurostimulation and digital
View HTML